AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|
21.7 C
New York
Friday, June 26, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1marketreleases

Craft Telemedicine Launches to Redefine Specialty Care with Human-Centered Platform

Revolutionary no-subscription telemedicine model gives patients complete control over specialized compounded medications and pharmacy choice. TULSA, Okla., June 25, 2025 /PRNewswire/ -- Craft Telemedicine today...

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

Hyundai Hope on Wheels donates $250,000 to BC Children’s Hospital Foundation to support children facing cancer

Every year in B.C., approximately 130 children are diagnosed with cancer. As the province's only full-service acute-care hospital dedicated to children, BC Children's Hospital...

Kirtland Credit Union Awards $10,000 in Scholarships to Four Outstanding Graduates

ALBUQUERQUE, N.M., June 25, 2025 /PRNewswire/ -- Kirtland Credit Union is proud to announce the recipients of its 2025 Scholarship Program, awarding $10,000 in...

Speranza Therapeutics and Sunshine Labs Announce Strategic Global Partnership to Expand Access to Life-Saving Harm Reduction Solutions

BOCA RATON, Fla. and TORONTO, June 25, 2025 /PRNewswire/ -- Speranza Therapeutics is proud to announce a strategic partnership with Sunshine Labs, a global leader...

Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON,...

Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON,...

Rosalind Franklin University Helix 51 Company UP Oncolytics Secures Wisconsin Economic Development Matching Grant to Advance Oncolytic Virus Therapy for Brain Cancer

NORTH CHICAGO, Ill., June 25, 2025 /PRNewswire/ -- UP Oncolytics, a neuro-oncology biotechnology company based in Milwaukee and a spin-out of the Advocate Aurora Research...

Novartis completes acquisition of Regulus Therapeutics

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

Slide Stainers Market to Reach $5.53 Billion by 2032, Growing at a CAGR of 7.9% from 2025, Says Meticulous Research®

Market Growth Driven by Rising Geriatric Population, Chronic Disease Burden, Laboratory Automation Demand, and Advanced Diagnostic Technology Integration REDDING, Calif., June 25, 2025 /PRNewswire/ -- According...

Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

MELBOURNE, Australia and INDIANAPOLIS, June 25, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its Telix Manufacturing...

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers